Why the study?
Do antithrombotic agents prevent deep-vein thrombosis and pulmonary embolism in patients undergoing elective hip replacement without increasing bleeding risk?
Do antithrombotic agents prevent deep-vein thrombosis and pulmonary embolism in patients undergoing elective hip replacement without increasing bleeding risk?
This text highlights the high risk of deep-vein thrombosis in elective hip replacement and the need for optimal prophylactic anticoagulation.
Answers are grounded in this paper and cite their sources.
Supports prophylaxis in elective hip replacement; leaves open optimal agent selection from higher-level trials.
Among patients undergoing elective hip replacement, the incidence of deep-vein thrombosis in the absence of prophylactic anticoagulation approaches 50 percent.1,2 Thrombus formation is multifocal, occurring principally in the surgically manipulated leg, where trauma to blood vessels and venous stasis would be expected to be most severe. Since approximately half of thrombi are found in large proximal veins, the risk of pulmonary embolism is high. An optimal therapeutic regimen should therefore be capable of preventing the initiation and propagation of venous thrombi without increasing the risk of perioperative bleeding or interfering with wound healing.The efficacy of several pharmacologic agents, . . .
No takes yet. Share an insight, caveat, or question.
Bruce M. Ewenstein (1997) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: